Reimbursement of Health Technologies

Keywords: reimbursement of generic medicines, insurance and new technologies, price regulation of new technologies, medicines parallel trade, cost-sharing and price elasticity of medicines.


The Economics of New Health Technologies. Incentives, organisation and Financing”, Oxford University Press, 2009 (co-editor Courbage, C and McGuire,A).



Regulation Effects on the Adoption of New Medicines” (with McGuire, A and Varol, N). Empirical Economics, 2015, 49(3): 1101-1121.

Price Regulation and Relative Delays in Generic Drug Adoption” (with McGuire, A and Varol, N). Journal of Health Economics, 2014, 38, 1-9.

Brand loyalty, patients and limited generic medicines uptake” (with Rudisill, C and Tan, S). Health Policy, 2014, 116 (2-3): 224–233.

The “Weisbrod Quadrilemma” revisited: insurance incentives on new health technologies” (with McGuire, A and Serra, V). Geneva Papers of Risk and Insurance, 2012, 37 (4): 678-95.

Does Cost Sharing really reduce Inappropriate Prescriptions among the Elderly?” (with M Gemmill-Toyama). Health Policy, 2011, 101 (2): 195-208.

Competition in off-patent drug markets: Issues, regulation and evidence” (with P Kanavos and L Sheeley). Economic Policy, 2008, 23(55): 497–538. [+ 100 Citations]

In Search of a Corrected Prescription Drug Elasticity Estimate: A Meta-Regression Approach” (with M Gemmill and A McGuire). Health Economics, 2007, 16(6): 627- 643.[+50 Citations]

Determinants of Out-of-pocket Pharmaceutical Expenditure and Access to Drugs in Catalonia” (with P Kanavos and J Rovira). Applied Economics, 2007, 39(5): 541-551.

Insurance Coverage and the Heterogeneity of Health and Drug Spending in the United States” (with P Kanavos and M Gemmill) Geneva Papers of Risk and Insurance, 2006, 31 (4): 669-691.

Pharmaceutical Parallel Trade in Europe: Impact on Stakeholders and Competition Effects” (with P Kanavos). Economic Policy, 2005, 20(44): 753-798. [+100 Citations]

Brief Articles

Is Medicines Parallel Trade ‘Regulatory Arbitrage’?International Journal of Health Economics and Management, 2016, 16 (4): 321-336.

Deregulation and Access to Medicines: The Peruvian Experience“. Journal of International Development, 2016, 28(6):997-1005.

Do International Launch Strategies of Pharmaceutical Corporations Respond to Changes in the Regulatory Environment?”(with Varol, N and McGuire, A) Applied Economic Perspectives and Policy, 2012, 34(3): 531-553.

Product differentiation, competition and regulation of new drugs: the case of statins in four European countries” (with P Kanavos and McGuire, A). Managerial and Decision Economics, 2007, 28(4-5):455-465.


Health Insurance and the uptake of new drugs in the United States” (with Victoria Serra and Marin Gemmill). In Costa-Font, J, Courbage, C and McGuire, A (eds). pp259-274. The Economics of New Health Technologies. Oxford University Press, 2009.

Pricing And Reimbursement Policies in Spain: Current and Future Trends” In Garau, M and Mestre, J (ed) European Medicines Pricing and Reimbursement. Now and the future. Radcliffe, London, 2006.